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Palacios-Gonzalez and Medina-Arellano present an insightful account of the world’s
first birth following the use of mitochondrial replacement techniques (MRT) by a US
doctor, Dr Zhang, through his affiliated clinic in Mexico. Their article contributes to
understanding the complex local and global landscapes of reproductive technologies,
and provides a counterbalance to the widely publicized statement that the US scien-
tists crossed borders to perform the procedure because there are ‘no rules’ in Mexico.
Their article is no doubt timely.Withmany other countries considering how to negoti-
ate MRTs within their own legal frameworks, the birth of the ‘first’ baby, alongside the
UK decision to explicitly legalize MRTs, could have international implications.1,2 By
focusing on the UK context and our own understanding ofMexican law, this comment
provides further explanation of the international significance of theMexico announce-
ment and the difficulties of responding to the rapid pace of development of genetic
technologies.
Palacios-Gonzalez and Medina-Arellano conclude that the scientists have acted il-
legally, breaching several provisions of the federal and state law.We do not wish to dis-
pute the authors’ interpretation of the law. However, we would like to suggest that an
alternative view of MRTs could lead to different legal conclusions concerning the law-
fulness of the technique in Mexico. The authors claim that the procedure conducted
by Dr Zhang violated the General Health Law and its accompanying Regulations on
1 I.G. Cohen & E.Y. Adashi. Preventing Mitochondrial DNA Diseases: One Step Forward, Two Steps Back, 316
JAMA, 273–4 (2016).
2 S. Varvasˇtian. UK’s Legalisation of Mitochondrial Donation in IVF Treatment: A Challenge to the International
Community or a Promotion of Life-saving Medical Innovation to be Followed by others?, 22 EUR. J HEALTH LAW
405–25 (2015).
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Health Research, because MRT is not an experimental procedure that ‘solves sterility
problems’. Furthermore, they claim that because it involves human subjects additional
sanctions for breaching the law will apply. The first claim, if accepted as correct, raises
questions about the process, in which pre-implantation genetic diagnosis (PGD) has
become approved inMexico. After all, PGD, likeMRTs (and unlike in vitro fertilisation
(IVF) or intracytoplasmic sperm injection (ICSI)) does not in itself treat infertility.
Nor is it possible to identify the precise moment, in which it became a fully acceptable
clinical procedure. This is because the clear distinction between research and clinical
practice stipulated in legal documents remains almost impossible to maintain in prac-
tice.This fluidity is exacerbated in the case of novel reproductive technologies, the full
consequences of which will not be known for years, or even generations, to come.With
regard to the second point, it could be argued, albeit controversially, that MRT con-
sists of several stages—the experimental stage involving modification of oocytes and
embryos (not considered persons under Mexican law) and the assisted reproduction
procedure itself (involving human subjects), which is a widely accepted medical prac-
tice. Of course, this interpretationmight seem far-fetched tomany. Alas, theUNESCO
andUN soft law instruments offer limited assistance and do not impose justiciable obli-
gations on Mexico. Therefore, the urgent need for national regulation of reproductive
technologies, voiced by the authors, is clear and undisputed. Can the UK example pro-
vide guidance in this respect?
In contrast to Mexico, where law concerning human reproduction remains scarce
andcontested, theUK legal position is unambiguous.TheHumanFertilisation andEm-
bryologyAct 1990prohibits germline geneticmodification.However, the 2008 amend-
ments opened the possibility for the UK government to legalize MRT, subject to Par-
liamentary approval. When the latter was obtained in February 2015, the UK became
the first country in the world to explicitly legalize MRTs.3 Whereas US reports about
MRT4 have mainly drawn on expert opinion and deliberation, the UK’s approach is
based on a model of public engagement and dialog.
TheUK has a history of close yet permissive regulation combined with a framework
for transparent public debate, and was therefore well placed to embark on the review
processwhich included explorationof the scientific state of the art and calls for evidence
to explore public attitudes and ethical implications. The Human Fertilisation and Em-
bryology Authority (HFEA), which regulates the use of gametes and embryos in the
UKwas responsible for gathering evidence on the safety and efficacy of the techniques,
and in the provision of clinical licenses. Four scientific reviews were organized by the
HFEA at the request of the Department of Health in 2011, 2013, 2014, and 2016.5
The reviews raised several questions relating to the novel features of mitochondria and
MRT.These included the risks of ‘carry over’ (where faultymitochondria could remain
attached to the nucleus during transfer) and the nature of the interactions between
3 C. Jones& I.Holme.Relatively (im)material: mtDNAandGenetic Relatedness in Law and Policy, 9 LIFESCI. SOC.
POL’Y 1–14 (2013).
4 NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE. MITOCHONDRIAL REPLACEMENT TECH-
NIQUES:ETHICAL, SOCIAL, ANDPOLICYCONSIDERATIONS (2016). doi: 10.17226/21871 (accessedApr. 24 2017).
5 HFEA. SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS TO AVOID MITOCHONDRIAL DISEASE
THROUGH ASSISTED CONCEPTION: 2016 (2016).
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mitochondrial DNA and nuclear DNA, recommendingmtDNA haplogroupmatching
‘as a precautionary measure’ (p7) when selecting a donor.
One of the most significant aspects of the review was the conclusion that there
was no scientific evidence to suggest differences in safety between maternal spindle
transfer (MST) and pronuclear transfer (PNT). On this basis, both techniques were
legalized, although the UK has continued to prioritize the development of PNT over
MST. Palacios-Gonzalez and Medina-Arellano’s article and the decision of the Jor-
danian family to use MST highlight that there are clearly ethical reasons why PNT,
which involves creating and destroying an embryo in the process, might attract more
objections.
The final UK scientific report published in 2016 agreed with the findings of the pre-
vious reports, concluding that the techniques were ‘not unsafe’. The ambiguity of this
statement highlights the difficulties of legislating for novel reproductive technologies. A
‘cautious’ approachwas recommended, but itwas ultimately considered appropriate ‘to
offer mitochondrial donation techniques as clinical risk reduction treatment for care-
fully selected patients’ (p7).The result is that in the UK only women at risk of having a
child with severe mitochondrial disease are legally allowed to access MRTs.
Alongside concerns about safety were discussions about the ethical issues ofMRTs.
Following their owncall for evidence, theNuffieldCouncil onBioethics6 identified sev-
eral ethical issues as significant, including the potential for harm, the implications for
the child’s identity, the relationship between child and donor, and because of germ line
changes, whether MRT represented a ‘slippery slope’ towards human enhancement
and manipulation of nuclear DNA.7 Despite differences between countries’ regulatory
structures, it is possible that such ethical concerns will be shared.8 The Council con-
cluded that it would be ethical for the techniques to be used by families as long as they
were considered safe and effective and families were offered support.
How or whether to monitor the health of the child and future generations was a
key concern throughout the mitochondria debates. Many wanted to avoid a repeat
of the US situation where it is only now that a project is underway to monitor the
health of surviving children born through a similar technique of cytoplasm injection in
2000.9,10 In theUK, theHFEA requires clinics to explain to the parents about the bene-
fits of follow-up, while noting that consent to follow-up cannot bemandatory.11 Zhang
has now provided further details of the procedure, and appears to be committed to
6 NUFFIELD COUNCIL ON BIOETHICS. NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHON-
DRIAL DNA DISORDERS: AN ETHICAL REVIEW. LONDON: NUFFIELD COUNCIL ON BIOETHICS (2012).
http://www.nuffieldbioethics.org/mitochondrial-dna-disorders (accessed July 6, 2017).
7 Also see A.L. Bredenoord,G. Pennings&G.DeWert.Ooplasmic andNuclear Transfer to PreventMitochondrial
DNA Disorders: Conceptual and Normative Issues, 14 HUMAN REPROD. UPDATE 669–78 (2008); Dimond R.
Social and Ethical Issues in Mitochondrial Donation, 115 BRIT. MED. BULL. 173–82 (2015).
8 R.J. Castro.Mitochondrial ReplacementTherapy: theUKandUSRegulatory Landscapes, 3 JLAWBIOSCI. 726-735
(2016).
9 J. Cohen J & M. Alikani.The biological basis for defining bi-parental or tri-parental origin of offspring from cyto-
plasmic and spindle transfer, 26 REPRODUCTIVE BIOMEDICINE ONLINE. 535–537 (2013).
10 J.A. Barritt et al.Mitochondria in Human Offspring Derived from Ooplasmic Transplantation: Brief Communica-
tion, 16 HUMAN REPROD. 513–6 (2001).
11 HFEA 2015. REGULATINGMITOCHONDRIAL DONATION (September 2015). HFEA (16/9/2015)764.
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tracking the health of the child.12,13 However, the Jordanian family have declined fur-
ther tests to assess levels of faulty mitochondrial DNA unless there are obvious health
benefits. Interestingly, this paper provides confirmation that Zhang has followed a sim-
ilar protocol to that which has been agreed in the UK, but the family’s reluctance to
submit for extensive testing highlights the reality of blurring health and illness in the
context of assisted reproduction. It also provides a reminder that for the first cohort
of any reproductive technology, there will always be a desire to collect evidence about
health and efficacy to inform future use, potentially leading to a tension between the
wishes of the family and those of the clinic or scientific institution.
As a baby born throughMRTwill inherit genetic material from three people, one of
themain questions throughout theMRTdebates was the nature of the relationship be-
tween child and donor.Media coverage was often dominated by headlines about ‘three
parent babies’, with the mitochondria donor identified as a ‘second mother’ or ‘third
parent’.14 But alarmist headlines aside, the question about genetic relatedness is of con-
siderable legal importance. Mitochondrial donation posed a challenge to the UK legal
framework because it involves the transfer of genetic but not nuclear material, and this
led to uncertainty as to how it should be conceptualized. Egg donation and tissue dona-
tion are dealt with in very different ways within UK law, particularly around anonymity
and access to information.TheHFEA15 has settled thematter in theUK, at least for the
time being, deciding that there was no legal obligation between the child and donor.
However, the child can have access to non-identifying information such as screening
tests, family health, and personal information provided by the donor, with the donor
having the right to know whether their donation has produced a child.16
Importantly, the UK situation highlights the factors that can facilitate support for
MRT and a change in law, and in this brief comment we highlight two aspects.The first
example is the Department of Health’s use of a particular definition of genetic modi-
fication17: ‘The working definition that we have adopted is that genetic modification
involves the germ-line modification of nuclear DNA (in the chromosomes) that can
be passed on to future generations. This will be kept under review’ (p15). This ‘work-
ing’ definition was closely aligned with approval for MRT because it ruled out MRT
from constituting genetic modification. The implication is that legalizing MRT would
not need to be disruptive, and it would not lead to the ‘slippery slope’ associated with
12 J. Zhang et al. Live Birth Derived from Oocyte Spindle Transfer to Prevent Mitochondrial Disease, 34 REPROD.
BIOMED. ONLINE 361–68 (2017).
13 M. Alikani et al. First Birth Following Spindle Transfer for Mitochondrial Replacement Therapy: Hope and Trepi-
dation, 34 REPROD. BIOMED. ONLINE 333–36 (2017).
14 R. Dimond & N.S. Stephens. Three Persons, Three Genetic Contributors, Three Parents: Mitochondrial
Donation, Genetic Parenting and the Immutable Grammar of the ‘Three x x’, HEALTH (2017). doi:
https://doi.org/10.1177/1363459316689380 (accessed July 6, 2017).
15 Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 (SI 2015/572)
http://www.legislation.gov.uk/uksi/2015/572/contents/made?page=5 (accessed July 6, 2017).
16 R. Dimond. Techniques of Donation: ‘Three parents’, Anonymity and Disclosure, 3 J MED. LAW ETHICS 165–73
(2015).
17 DEPARTMENT OF HEALTH. MITOCHONDRIAL DONATION: GOVERNMENT RESPONSE TO THE CONSULTATION ON
DRAFT REGULATIONS TO PERMIT THE USE OF NEW TREATMENT TECHNIQUES TO PREVENT THE TRANSMISSION OF A
SERIOUS MITOCHONDRIAL DISEASE FROM MOTHER TO CHILD 22 JULY 2014. https://www.gov.uk/government/
consultations/serious-mitochondrial-disease-new-techniques-to-prevent-transmission (accessed July 6,
2017).
MRT and the birth of the ‘first’  5
human modification (which is particularly associated with modifying nuclear genes).
By supporting this definition, the government were accused of misleading the public,
dishonesty, and acting by stealth.18
Secondly, the UK debates involved emotional appeals in support of the change in
law. Mitochondrial disease was presented as affecting the lives of thousands of women
and MRT as having the potential to eliminate mitochondrial disease from families. 19
The debates were dominated by emotive narratives of patient suffering, with parents of
critically ill children appearing in news reports and public meetings around the time of
the parliamentary debates. Their stories, always in support of MRT, were much more
powerful than the arguments presented by those who stood against the change. As a
result, MRT became erroneously synonymized as a treatment and cure for children al-
ready bornwith the disease, and opposition needed to be carefully negotiated.This was
evident from a House of Commons debate where one MP stated ‘I simply do not un-
derstand how opponents of this [MRT] can argue that they want to continue to inflict
that sort of suffering on so many children’.20
The Mexico case provides an opportunity to question national regulatory ap-
proaches within the rapidly developing global landscape of genetic intervention. It
highlights the importance, but also the practical difficulties, of supporting transnational
law, which regulates cross-border flows of human tissue, people, services, and knowl-
edge. Practicing lawyers have been grappling with these issues for years, but the theo-
retical debates are still underdeveloped.
Dr Zhang was heavily criticized not just for apparently circumventing US law, but
also for not following scientific etiquette, particularly in relation to transparency in re-
lation to how he carried out the techniques, announced the birth and published the
scientific details. Dr Zhang’s recently published account of the process does not refer
to the legality of his position and this is where Palacios-Gonzalez andMedina-Arellano
have been able to contribute to the debate.They raise a legitimate concern that Zhang’s
work will lead to conservative restrictions on reproductive science affecting scientific
progress in Mexico which would also have a direct effect on Zhang’s Mexican clinic.
However, the hope is that every conservative turn can also bring a more liberal wave.
MRTis a contemporary technology,whichhas challenged legal frameworks andpre-
vailing cultural assumptions about the symbolic and biological significance of genetic
material. Formany, themitochondria debates and theUK position towardsMRT con-
tinue to prove that the UK is a ‘gold standard’ in reproductive regulation. It can be
difficult to make comparisons between countries, such as Mexico and the UK, which
have very particular legal traditions and where the law operates within an entirely dif-
ferent socio-political and moral context. Mexico has a deeply Catholic, traditional so-
ciety, where debates about sexuality and reproduction are highly politicized. Within
this context, and despite a general agreement that regulation is needed, doctors and
18 S. Connor, Exclusive: Scientists Accuse Government of Dishonesty over GM Babies in its Regulation of
New IVF Technique, THE INDEPENDENT, July 28, 2014. http://www.independent.co.uk/news/science/
exclusive-scientists-accuse-government-of-dishonesty-over-gm-babies-in-its-regulation-of-new-ivf-9631807.
html (accessed July 6, 2017).
19 G.S. Gorman et al. Mitochondrial Donation: How Many Women could Benefit?, 372 N ENGL J MED. 885–7
(2015).
20 HouseofCommonsdebate, 1Sep2014 :Column103.http://hansard.parliament.uk/Commons/2014-09-01/
debates/14090125000001/MitochondrialReplacement(PublicSafety) (accessed July 6, 2017).
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scientists can be reluctant to pursue legislative aims because of the risk of greater re-
striction. In this kind of climate, suggestions about a straightforward adoption of the
UK model of liberal regulation to other jurisdictions should be made with extreme
caution.
It is significant to note that theMexico case exposed an extended time lag: when the
birth of the ‘first’ was announced, no clinics had yet been licensed in theUK, despite the
fact that the techniques by then were legal.Whereas some claimed that the UK process
was excessively labored (and conversely, others considered it rushed), time will tell as
towhether theUKposition onMRTbecomes an exemplar for others of how regulation
can foster innovation.21
It is therefore important to note the particular context of UK biopolitics which fa-
cilitatedMRT legalization—close yet permissive regulation; experience of conducting
scientific and ethical reviews; an active and organized patient cohort; resources for sup-
porting the review process, developing science and clinical care; andmost importantly,
the political will to support change. MRT research was extensively funded through the
WellcomeTrust andMuscular DystrophyUK, resources were available to carry out re-
views and assess evidence, and the National Health Service has agreed to fund clinical
services. Although commercial interests have not been key features of the discussions
within the UK context, it is possible that fostering better international collaboration,
and enhancing procedural transparency, could prove extremely valuable in guiding fu-
ture progress.What is clear from thesediscussions is that legalizationwithin theUK, the
role ofMexico in the ‘first’ birth, the use ofMRT inUkraine for fertility issues22 (which
would be illegal in the UK), and the development of gene editing technologies (which
has much wider applicability for both human health, embryo research and human en-
hancement) inform a new international landscape ofMRT technologies and bringwith
it new global challenges.
21 S.H. Harmon & D. Kale. Regulating in Developing Countries: Multiple Roles for Medical Research and Products
Regulation in Argentina and India, 43 TECH. SOC. 10–22 (2015).
22 A.Coghlan,Exclusive: ‘3-parent’ BabyMethodAlreadyused for Infertility,NEWSCIENTIST,Oct. 10, 2016. https://
www.newscientist.com/article/2108549-exclusive-3-parent-baby-method-already-used-for-infertility/ (ac-
cessed Oct. 24, 2016).
